About this trial
The goal of this clinical trial is to determine the most effective timing for clipping in adults with ruptured intracranial aneurysms. It will also assess the safety of performing the surgery at different times of early period after the aneurysm has ruptured. The main questions it aims to answer are:
1. Does ultra-early surgical intervention ( less than 24 hours of rupture) improve survival rates compared to delayed surgery (24 to 72 hours after rupture)? 2. What are the complication rates associated with early versus delayed surgical intervention?
Researchers will compare clipping in ultra-early period to surgery in early period to see if timing affects the outcomes for treating ruptured intracranial aneurysms.
Participants will:
* Be randomly assigned to undergo surgical clipping either within 24 hours of rupture or between 24 hours to 72 hours after the rupture. * Visit the clinic for follow-up assessments at 1 month, 3 months, 6 months, and 12 months post-surgery. * Keep a diary of their symptoms, neurological function, and any complications they experience post-surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
aneurysmal subarachnoid hemorrhage
patient eligible for surgical clipping
patients with informed consent for inclusion into the study
Disqualifiers
patients admitted and treated >72 h after subarachnoid hemorrhage onset
patients with severe comorbidities
patients with multiple aneurysms
Trial design
Parallel
Treatments tested in this trial
Ultra early (<24 hours) ruptured aneurysm clipping
Procedure/SurgeryAneurysms are clipped with open surgery in less than 24 hours after rupture to prevent early rebleeding.
Early (24-72 hours) ruptured aneurysm clipping
Procedure/SurgeryAneurysms are clipped with open surgery in 24 to 72 hours after rupture to prevent early rebleeding.
Treatment groups
Trial outcomes
Primary outcomes
Rebleeding rate before anerysm clipping
The rate of recurrent aneurysm rupture and subarachnoid hemorrhage before aneurysm surgery is performed.
Secondary outcomes
Clinical outcome according to the Modified Rankin Scale
Modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0 to 6, spanning from perfect health without symptoms to death: 0: No symptoms. 1. No significant disability. Able to carry out all usual activities, despite some symptoms. 2. Slight disability. Able to look after own affairs without assistance but unable to carry out all previous activities. 3. Moderate disability. Requires some help, but able to walk unassisted. 4. Moderately severe disability. Unable to attend to own bodily needs without assistance and unable to walk unassisted. 5. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. Dead.
Delayed cerebral ischemia
Delayed cerebral ischemia is defined as a clinical deterioration attributed to cerebral ischemia that occurs days after an initial subarachnoid hemorrhage. This condition is characterized by a new onset of focal neurological impairment or a decrease of at least two points on the Glasgow Coma Scale, which cannot be attributed to other causes such as rebleeding, hydrocephalus, or surgical complications. The risk of delayed cerebral ischemia is lower when aneurysms are treated in less than 24 h after rupture
Rate of occlusion according to modified Raymond-Roy classification
Modified Raymond-Roy Classification (mRRC) categorizes the occlusion status of an aneurysm post-treatment into three grades based on the extent of filling within the aneurysm sac seen on angiographic imaging: Class 1 (Complete Occlusion): No opacification of the aneurysm sac is visible. This indicates a complete absence of blood flow into the aneurysm. Class 2 (Residual Neck): A small residual contrast filling is confined to the neck of the aneurysm. Class 3 (Residual Aneurysm): There is opacification of the aneurysm sac, indicating incomplete occlusion with more substantial contrast filling.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Revaz Dzhindzhikhadze
Lead sponsor
Moscow Regional Research and Clinical Institute (MONIKI)
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options: